Dake Benjamin T's Form 4 filing
Jade Biosciences, Inc. (JBIO) · filed Aug 12, 2022
- Accession no.
- 0001493152-22-022415
- Filed
- Aug 12, 2022
- Trade date
- Aug 10-11, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 6 non-derivative transactions and 2 derivative transactions. Open-market sales total $338.6K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Dake Benjamin TCIK 0001869248 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 10, 2022 | Common Stock | MOption exerciseAcquired | +12,720 | $1.74 | +$22,132.8 | 12,720 | Direct | |
| Aug 10, 2022 | Common Stock | SSaleDisposed | −11,940 | $24.06F2 | −$287,276.4 | 780 | Direct | |
| Aug 10, 2022 | Common Stock | SSaleDisposed | −780 | $24.48F3 | −$19,094.4 | 0 | Direct | |
| Aug 11, 2022 | Common Stock | MOption exerciseAcquired | +1,347 | $1.74 | +$2,343.78 | 1,347 | Direct | |
| Aug 11, 2022 | Common Stock | SSaleDisposed | −1,268 | $23.89F4 | −$30,292.52 | 79 | Direct | |
| Aug 11, 2022 | Common Stock | SSaleDisposed | −79 | $24.55 | −$1,939.45 | 0 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 10, 2022 | Common Stock | MOption exerciseDisposed | −12,720 | $0.00 | $0 | 19,930 | Direct | |
| Aug 11, 2022 | Common Stock | MOption exerciseDisposed | −1,347 | $0.00 | $0 | 18,583 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.43 to $24.40, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.435 to $25.15, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.47 to $24.26, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
Remarks
Officer Title: President, Chief Operating Officer and Secretary